50 related articles for article (PubMed ID: 24201550)
1. The Diagnostic Value of
Bang JI; Park S; Kim K; Seo Y; Chong A; Hong CM; Choi M; Lee SW; Oh SW
Thyroid; 2023 Oct; 33(10):1224-1236. PubMed ID: 37597200
[No Abstract] [Full Text] [Related]
2. Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study.
Kist JW; de Keizer B; Stokkel MP; Hoekstra OS; Vogel WV;
BMC Cancer; 2014 Jun; 14():405. PubMed ID: 24906384
[TBL] [Abstract][Full Text] [Related]
3. Incremental diagnostic value of [
Dittmann M; Gonzalez Carvalho JM; Rahbar K; Schäfers M; Claesener M; Riemann B; Seifert R
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2639-2646. PubMed ID: 32248325
[TBL] [Abstract][Full Text] [Related]
4. Tumor Burden of Iodine-Avid Bone Metastatic Thyroid Cancer Identified via
Nappi C; Zampella E; Gaudieri V; Volpe F; Piscopo L; Vallone C; Pace L; Ponsiglione A; Maurea S; Nicolai E; Cuocolo A; Klain M
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38276075
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of 68 Ga-NODAGA-RGD PET-CT in patients of carcinoma thyroid with thyroglobulin elevated negative radioiodine scintigraphy (TENIS) with a head-to-head comparison with FDG-PET/CT.
Gondhane A; Verma P; Chandak A; Basu S
Nucl Med Commun; 2024 May; 45(5):412-419. PubMed ID: 38445350
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Performance of [
Ventura D; Dittmann M; Büther F; Schäfers M; Rahbar K; Hescheler D; Claesener M; Schindler P; Riemann B; Seifert R; Roll W
J Nucl Med; 2024 Feb; 65(2):192-198. PubMed ID: 38164565
[TBL] [Abstract][Full Text] [Related]
7. Application of Pet-CT Fusion Deep Learning Imaging in Precise Radiotherapy of Thyroid Cancer.
Lin Q; Qi Q; Hou S; Chen Z; Jiang N; Zhang L; Lin C
J Healthc Eng; 2021; 2021():2456429. PubMed ID: 34413967
[TBL] [Abstract][Full Text] [Related]
8. [
Yechiel Y; Keidar Z; Weiler-Sagie M
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):624-625. PubMed ID: 36222854
[No Abstract] [Full Text] [Related]
9. Positron Emission Tomography/Computed Tomography in Thyroid Cancer: An Updated Review.
Chandekar KR; Satapathy S; Bal C
PET Clin; 2024 Apr; 19(2):131-145. PubMed ID: 38212213
[TBL] [Abstract][Full Text] [Related]
10. The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis.
Giovanella L; Garo ML; Albano D; Görges R; Ceriani L
Endocr Connect; 2022 Apr; 11(4):. PubMed ID: 35245206
[TBL] [Abstract][Full Text] [Related]
11. The role of Tg kinetics in predicting 2-[
Albano D; Tulchinsky M; Dondi F; Mazzoletti A; Bertagna F; Giubbini R
Endocrine; 2021 Nov; 74(2):332-339. PubMed ID: 34014437
[TBL] [Abstract][Full Text] [Related]
12. Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [
Albano D; Tulchinsky M; Dondi F; Mazzoletti A; Lombardi D; Bertagna F; Giubbini R
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):461-468. PubMed ID: 32794104
[TBL] [Abstract][Full Text] [Related]
13. Appraisal of radioiodine refractory thyroid cancer: advances and challenges.
Liu H; Yang D; Li L; Tu Y; Chen C; Sun S
Am J Cancer Res; 2020; 10(7):1923-1936. PubMed ID: 32774993
[TBL] [Abstract][Full Text] [Related]
14. The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer.
Terroir M; Borget I; Bidault F; Ricard M; Deschamps F; Hartl D; Tselikas L; Dercle L; Lumbroso J; Baudin E; Berdelou A; Deandreis D; Schlumberger M; Leboulleux S
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):638-646. PubMed ID: 27796544
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Consecutive Serum Thyroglobulin Levels During Hormone Withdrawal and Failure of Initial Radioiodine Ablation in Thyroid Cancer Patients.
Yoon H; Kim SH; O JH; Seo YY; Lee Y; Kim H; Ryu J
Nucl Med Mol Imaging; 2015 Dec; 49(4):276-83. PubMed ID: 26550046
[TBL] [Abstract][Full Text] [Related]
16. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications.
Spencer C; Petrovic I; Fatemi S; LoPresti J
J Clin Endocrinol Metab; 2014 Dec; 99(12):4589-99. PubMed ID: 25226290
[TBL] [Abstract][Full Text] [Related]
17. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies.
Spencer C; LoPresti J; Fatemi S
Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):394-404. PubMed ID: 25122493
[TBL] [Abstract][Full Text] [Related]
18. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions.
Kelders A; Kennes LN; Krohn T; Behrendt FF; Mottaghy FM; Verburg FA
Nucl Med Commun; 2014 Feb; 35(2):176-81. PubMed ID: 24201550
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
